pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-2628Research ArticleОБЗОРЫREVIEWЭффективность тиотропиума бромида по влиянию на параметры функции внешнего дыхания: данные клинических исследованийA Influence of Spiriva on lung function parameters: clinical research dataАйсановЗ. Р.AisanovZ. R.
Москва
НИИ пульмонологии Минздрава РФRussian Federation20030309202105105110Copyright © Айсанов З.Р., 20212021Айсанов З.Р.Aisanov Z.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2628
.
ReferencesAmerican Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care. Med. 1995; 152: S77-S120.American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care. Med. 1995; 152: S77-S120.Barnes P.J., Belvisi M.G., Mak J.C.W. et al. Tiotropium bromide (Ba 679 Br), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sei. 1995; 56: 853-859.Barnes P.J., Belvisi M.G., Mak J.C.W. et al. Tiotropium bromide (Ba 679 Br), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sei. 1995; 56: 853-859.Barnes P.J. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: S72-S79.Barnes P.J. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: S72-S79.Barnes P.J. The pharmacological properties of tiotropium. Chest 2000; 117: S63-S66.Barnes P.J. The pharmacological properties of tiotropium. Chest 2000; 117: S63-S66.Calverley P.M. The future for tiotropium. Ibid. S67-S69.Calverley P.M. The future for tiotropium. Ibid. S67-S69.Casaburi R., Briggs D.D.Jr., Donohue J.F. et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Ibid. 118: 1294-1302.Casaburi R., Briggs D.D.Jr., Donohue J.F. et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Ibid. 118: 1294-1302.Casaburi R., Mahler D.A., Jones P.W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.Casaburi R., Mahler D.A., Jones P.W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.Celli B., ZuWallack R.t Wang S., Keste S. Improvements in inspiratory capacity with tiotropium in patients with COPD. Ibid. (suppl.): 3079.Celli B., ZuWallack R.t Wang S., Keste S. Improvements in inspiratory capacity with tiotropium in patients with COPD. Ibid. (suppl.): 3079.Disse B., Raichl R., Speck G.A. et al. BA679BR, a novel anticholinergic bronchodilator. Life Sci. 1993; 52: 537-544.Disse B., Raichl R., Speck G.A. et al. BA679BR, a novel anticholinergic bronchodilator. Life Sci. 1993; 52: 537-544.Disse B., Speck G.A., Rominger K.L. et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Ibid. 1999; 64: 457-464.Disse B., Speck G.A., Rominger K.L. et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Ibid. 1999; 64: 457-464.Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.ERS Consensus Statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 1995; 8: 1398-1420.ERS Consensus Statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 1995; 8: 1398-1420.Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (executive summary). Bethesda, MD: National Institutes of Health; 2001.Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (executive summary). Bethesda, MD: National Institutes of Health; 2001.Gross N.J., Skorodin M.S. Role of the parasympathetic system in airway obstruction due to emphysema. N. Engl. J. Med. 1984; 311: 421-425.Gross N.J., Skorodin M.S. Role of the parasympathetic system in airway obstruction due to emphysema. N. Engl. J. Med. 1984; 311: 421-425.Haddad E.B., Mak J.C.W., Barnes P.J. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol. Pharmacol. 1994; 45: 899-907.Haddad E.B., Mak J.C.W., Barnes P.J. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol. Pharmacol. 1994; 45: 899-907.Joos G.F. Potential usefulness of inhibiting neural mechanisms in asthma. Monaldi Arch. Chest. Dis. 2000; 55: 411-414.Joos G.F. Potential usefulness of inhibiting neural mechanisms in asthma. Monaldi Arch. Chest. Dis. 2000; 55: 411-414.Karpel J.P. Bronchodilator responses to anticholinergic andadrenergic agents in acute and stable COPD. Chest 1991; 99: 871-876.Karpel J.P. Bronchodilator responses to anticholinergic andadrenergic agents in acute and stable COPD. Chest 1991; 99: 871-876.LeDoux E.J., Morris J.F., Temple W.P. et al. Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD. Ibid. 1989; 95: 1013-1016.LeDoux E.J., Morris J.F., Temple W.P. et al. Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD. Ibid. 1989; 95: 1013-1016.Lefkowitz R.J., Hoffman B.B., Taylor P. Neurohumoral transmission: the autonomic and somatic motor nervous systems. In: Gilman A.G. et al. eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. Elmsford, NY: Pergamon Press, Inc.; 1990. 84-121.Lefkowitz R.J., Hoffman B.B., Taylor P. Neurohumoral transmission: the autonomic and somatic motor nervous systems. In: Gilman A.G. et al. eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. Elmsford, NY: Pergamon Press, Inc.; 1990. 84-121.Littner M.R., Ilowite J.S., Tashkin D.P. et al. Long-acting bronchodilation with once daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1136-1142.Littner M.R., Ilowite J.S., Tashkin D.P. et al. Long-acting bronchodilation with once daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1136-1142.Maesen F., Smeets J., Sledsens T. et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 1995; 8: 1506-1513.Maesen F., Smeets J., Sledsens T. et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 1995; 8: 1506-1513.O'Connor B.J., Towse L.J., Barnes P.J. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med. 1996; 154: 876-880.O'Connor B.J., Towse L.J., Barnes P.J. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med. 1996; 154: 876-880.O'Donnel D.E., Helgo M agnussen H., Gerken F. et al. Mechanisms of improved exercise tolerance in COPD in response to tiotropium. Eur. Respir. J. 2002; 19 (suppl.): 1826.O'Donnel D.E., Helgo M agnussen H., Gerken F. et al. Mechanisms of improved exercise tolerance in COPD in response to tiotropium. Eur. Respir. J. 2002; 19 (suppl.): 1826.Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. ATS statement. Am J. Respir. Crit. Care Med. 1995; 152: S77-S120.Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. ATS statement. Am J. Respir. Crit. Care Med. 1995; 152: S77-S120.Van Noord J.A., Bantje Th.A., Eland M.E. et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000; 55: 289-294.Van Noord J.A., Bantje Th.A., Eland M.E. et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000; 55: 289-294.Vincken W., van Noord J.A., Greefhorst A.P.M. et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209-216.Vincken W., van Noord J.A., Greefhorst A.P.M. et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209-216.
The authors declare that there are no conflicts of interest present.